首页> 美国卫生研究院文献>OncoTargets and therapy >Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials

【2h】

Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials

机译：血管内皮生长因子受体酪氨酸激酶抑制剂治疗相关死亡的风险：41项随机对照试验的荟萃分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundVascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) have widely been used in advanced cancer. However, these drugs may also lead to serious adverse events. The present meta-analysis aimed to determine the overall incidence and risk of deaths due to VEGFR-TKIs with more detailed subgroup analysis.

机译：背景技术血管内皮生长因子受体（VEGFR）酪氨酸激酶抑制剂（TKIs）已广泛用于晚期癌症。但是，这些药物也可能导致严重的不良事件。本荟萃分析旨在通过更详细的亚组分析来确定VEGFR-TKIs引起的总体发病率和死亡风险。

著录项

期刊名称 OncoTargets and therapy
作者
Shaodong Hong; Wenfeng Fang; Wenhua Liang; Yue Yan; Ting Zhou; Tao Qin; Xuan Wu; Yuxiang Ma; Yuanyuan Zhao; Yunpeng Yang; Zhihuang Hu; Cong Xue; Xue Hou; Yue Chen; Yan Huang; Hongyun Zhao; Li Zhang;
展开▼
作者单位

展开▼
年(卷),期 2014(7),-1
年度 2014
页码 1851–1867
总页数 9
原文格式 PDF
正文语种
中图分类应用微生物学;肿瘤学;
关键词
cancer tyrosine kinase inhibitors treatment-related death meta-analysis;

机译：癌症;酪氨酸激酶抑制剂;与治疗有关的死亡;荟萃分析;

相似文献

外文文献
中文文献
专利

1. Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials [J] . Shaodong Hong, Wenfeng Fang, Wenhua Liang, OncoTargets and therapy . 2014,第4期

机译：血管内皮生长因子受体酪氨酸激酶抑制剂治疗相关死亡的风险：41项随机对照试验的荟萃分析
2. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors [J] . SchutzF.A.B., JeY., RichardsC.J., Journal of Clinical Oncology . 2012,第8期

机译：血管内皮生长因子酪氨酸激酶抑制剂治疗的癌症患者随机对照试验的Meta分析
3. Risk of gastrointestinal events with newly approved (after 2011) vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials [J] . Li Jing, Gu Jian European journal of clinical pharmacology . 2017,第10期

机译：新批准的胃肠事件风险（2011年以后）血管内皮生长因子受体酪氨酸激酶抑制剂在癌症患者：随机对照试验的荟萃分析
4. MULTI-CENTER, PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED STUDY OF ORAL TOCERANIB PHOSPHATE (PALLADIATM, SU11654), A RECEPTOR TYROSINE KINASE INHIBITOR, FOR THE TREATMENT OF DOGS WITH RECURRENT MAS [C] . Cheryl L London, Carolyn J Henry, Anthony W Rusk, Annual conference of the Veterinary Cancer Society . 2008

机译：多中心，安慰剂对照，双盲，随机研究口服Toceranib磷酸盐（Palladia TM，SU11654），受体酪氨酸激酶抑制剂，用于治疗经常性MAS的狗
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients [O] . Bo Liu, Fengxia Ding, Yang Liu, 2016

机译：与癌症患者血管内皮生长因子受体酪氨酸激酶抑制剂相关的高血压的发病率和风险：涉及30013名患者的72项随机对照试验的综合网络荟萃分析
7. Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in the treatment of advanced thyroid cancer: a meta-analysis of randomized controlled trials [O] . Hao Wen, Wufuer Yimaer, Aizizi ABuDuReYiMu, 2016

机译：血管内皮生长因子受体酪氨酸激酶抑制剂治疗晚期甲状腺癌的疗效和安全性：随机对照试验的荟萃分析

Risk of treatment-related deaths with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis of 41 randomized controlled trials

摘要

著录项

相似文献

相关主题

期刊订阅